Wuhan Createrna Science and Technology Co.,Ltd. is an innovative drug research and development company. Adhering to the dual-driven strategy of simultaneous improvement of R&D pipeline and platform construction, Createrna has built a new drug R&D system covering the whole process from POC, candidate compound screening, preclinical druggability development to clinical research.
-
240+
Employee
-
180+
Researchers
-
15+
Projects
-
25+
Pipelines
-
300+
Partners
Science
Research Ability
The whole process of research and development from candidate compound screening, preclinical druggability development to clinical research.
Pipeline
Createrna has built a rich pipeline of drug research and development varieties
Currently, Createrna has several projects under research in essential hypertension, chronic heart failure, anticoagulation and other indications, and has entered the clinical research stage.
Createrna is researching in IgA nephropathy, FSGS, diabetic nephropathy and other indications.
Createrna has a number of projects in chronic cough and idiopathic pulmonary fibrosis, and has already entered the clinical and IND phase.
Createrna has several drugs for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, etc., and several projects have entered the clinical research stage.
Preclinical/IND
I Clinical Phase
II Clinical Phase
III Clinical Phase
Product Launch
Preclinical/IND
I Clinical Phase
II Clinical Phase
III Clinical Phase
Product Launch
Preclinical/IND
I Clinical Phase
II Clinical Phase
III Clinical Phase
Product Launch
Preclinical/IND
I Clinical Phase
II Clinical Phase
III Clinical Phase
Product Launch
News Activity
News Center
-
2021-08-11
MY004567 tablets was clinically approved by FDS
-
2022-02-16
The application for clinical trial of MY008211A tablet was officially accepted by the State Food and Drug Administration
-
2022-07-17
MY004567 tablets was approved by the FDA US. for clinical trials implied
-
2023-06-25
Createrna Announces Completion of Series A Financing at Its Strategic Investment Press Conference in Wuhan
-
2023-09-28
Createrna Receives Capital Injection from Well-known Investment Institutions
Contact Us
Contact Us
-
Consulting
-
Business Cooperation
-
Investor Consultation
-
-
Job Recruitment
-
Wuhan Createrna
-
Shanghai Meiyue
-
-
Contact Us
-
Contact Tel No
-